News – MedLumics

05 mar 2025

Medlumics ^® Announces the publication of FIM results for the Ablaview ^® (PF) Ablation System in (AF) Patients, including Clinical Safety and our ability to predict durable lesions at 3 motnh with 100% speceficity

We would like to thank the investigation site team and particularly the investigators and proctors in this groundbreaking first-in human trial and for enabling the publication of these important validating results. Peter Hinchliffe, CEO MedLumics “ Join us as we raise our Series B funding of €15m to reach our regulatory clinical trial readiness milestone. We are ready to move forward with these results toward treating the 100 million Atrial Fibrillation patients globally ” ….

19 Dec 2024

Medlumics is proud to announce the completion of the FIM study, with successful remapping at 3 months, demostrating the efficacy of the AblaView ® optically guided Pulsed Field Ablation (PFA) system and presentation at the AF Symposium 2025.

“ This is key milestone in validating a definitive Atrial Fibrillation (AF) ablation system using PFA and Optical Coherence Reflectometry(OCR) to monitor and confirm the success of ablation under direct vision in real time ” Peter Hinchliffe CEO MdLumics, …

29 Oct 2024

Medlumics new CEO and Board Member announces 10 patients treated in First in Man (FIM) clinical trial with the real-time visually guided AblaView PFA System .

MedLumics, a medical device company developing fiber optically guided platform technologies for the treatment, initially, of Atrial fibrillation (AF), announced today 10 patients treated in the company’s First in Man clinical trial….

29 Jul 2024

CDTI Innovación invests in Medlumics together with Asabys and CRITERIA Bio Ventures

CDTI Innovación, through its invierte program, together with Asabys Partners, through its venture capital funds Sabadell Asabys Health Innovation Investments SCR, S.A. and Asabys Top UP Fund FCR ….

10 Feb 2021

Medlumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman

Financing round closes at EUR 18M to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation ….

More News

Esta empresa está capitalizada por Innvierte, un programa de inversión del CDTI, E.P.E.

Pulseview - Un sistema eficaz y seguro para el tratamiento de la Fibrilación Auricular a través de electroporación irreversible de Ablación. CPP2021-008480. Programa Estatal para impulsar la investigación Científico-Técnica y su Transferencia, en el marco del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023.

Financiado por la Unión Europea – NextGenerationEU

Ablaview - Un sistema innovador de Ablación por Radio-Frecuencia guiado por Imagen para el Tratamiento de la Fibrilación Auricular. RTC-2016-5445-1 Retos Colaboración 2016.

© MedLumics 2023

Contact

Work with us

Legal Notice

Privacy Policy

Cookies Policy

© MedLumics 2023

Contact

Work with us

Legal Notice

Privacy Policy

Cookies Policy

This site is intended for Healthcare professionals only. MedLumics S.L. is a pre-commercial, medical device company that designs and manufactures catheter-based systems for the treatment of supra-ventricular tachycardias. MedLumics products are currently for investigation purposes and are intended to be used by trained professionals. MedLumics is committed to transform progress in the science and technology of light into high-quality innovative products improving human living standards worlwide.